» Articles » PMID: 30615425

A Supramolecular Nanocarrier for Delivery of Amiodarone Anti-Arrhythmic Therapy to the Heart

Overview
Journal Bioconjug Chem
Specialty Biochemistry
Date 2019 Jan 8
PMID 30615425
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Amiodarone is an effective antiarrhythmic drug used to treat and prevent different types of cardiac arrhythmias. However, amiodarone can have considerable side effects resulting from accumulation in off-target tissues. Cardiac macrophages are highly prevalent tissue-resident immune cells with importance in homeostatic functions, including immune response and modulation of cardiac conduction. We hypothesized that amiodarone could be more efficiently delivered to the heart via cardiac macrophages, an important step toward reducing overall dose and off-target tissue accumulation. Toward this goal, we synthesized a nanoparticle drug carrier composed of l-lysine cross-linked succinyl-β-cyclodextrin that demonstrates amiodarone binding through supramolecular host-guest interaction as well as a high macrophage affinity. Biodistribution analyses at the organ and single-cell level demonstrate accumulation of nanoparticles in the heart resulting from rapid uptake by cardiac macrophages. Nanoparticle assisted delivery of amiodarone resulted in a 250% enhancement in the selective delivery of the drug to cardiac tissue in part due to a concomitant decrease of pulmonary accumulation, the main source of off-target toxicity.

Citing Articles

Cyclodextrin Nanoparticles and Injectable Polymer-Nanoparticle Hydrogels for Macrophage-Targeted Delivery of Small-Molecule Drugs.

Soni S, Rodell C Methods Mol Biol. 2025; 2902:117-131.

PMID: 40029599 DOI: 10.1007/978-1-0716-4402-7_7.


Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging.

Alradwan I, Al Fayez N, Alomary M, Alshehri A, Aodah A, Almughem F Pharmaceutics. 2024; 16(8).

PMID: 39204382 PMC: 11360443. DOI: 10.3390/pharmaceutics16081037.


How do lipid-based drug delivery systems affect the pharmacokinetic and tissue distribution of amiodarone? A comparative study of liposomes, solid lipid nanoparticles, and nanoemulsions.

Khaleseh F, Barzegar-Jalali M, Zakeri-Milani P, Karami Z, Saghatchi Zanjani M, Valizadeh H Iran J Basic Med Sci. 2024; 27(7):857-867.

PMID: 38800017 PMC: 11127074. DOI: 10.22038/IJBMS.2024.75152.16292.


Host-functionalization of macrin nanoparticles to enable drug loading and control tumor-associated macrophage phenotype.

Sarkar B, Arlauckas S, Cuccarese M, Garris C, Weissleder R, Rodell C Front Immunol. 2024; 15:1331480.

PMID: 38545103 PMC: 10965546. DOI: 10.3389/fimmu.2024.1331480.


Understanding the in vivo Fate of Advanced Materials by Imaging.

Li R, Ng T, Garlin M, Weissleder R, Miller M Adv Funct Mater. 2024; 30(37).

PMID: 38545084 PMC: 10972611. DOI: 10.1002/adfm.201910369.


References
1.
Guimaraes P, Tan M, Tammela T, Wu K, Chung A, Oberli M . Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes. J Control Release. 2018; 290:75-87. PMC: 6441337. DOI: 10.1016/j.jconrel.2018.09.025. View

2.
Miller M, Chandra R, Cuccarese M, Pfirschke C, Engblom C, Stapleton S . Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts. Sci Transl Med. 2017; 9(392). PMC: 6681815. DOI: 10.1126/scitranslmed.aal0225. View

3.
Takahama H, Shigematsu H, Asai T, Matsuzaki T, Sanada S, Fu H . Liposomal amiodarone augments anti-arrhythmic effects and reduces hemodynamic adverse effects in an ischemia/reperfusion rat model. Cardiovasc Drugs Ther. 2013; 27(2):125-32. DOI: 10.1007/s10557-012-6437-6. View

4.
Zhuge Y, Zheng Z, Xie M, Li L, Wang F, Gao F . Preparation of liposomal amiodarone and investigation of its cardiomyocyte-targeting ability in cardiac radiofrequency ablation rat model. Int J Nanomedicine. 2016; 11:2359-67. PMC: 4892840. DOI: 10.2147/IJN.S98815. View

5.
King K, Aguirre A, Ye Y, Sun Y, Roh J, Ng Jr R . IRF3 and type I interferons fuel a fatal response to myocardial infarction. Nat Med. 2017; 23(12):1481-1487. PMC: 6477926. DOI: 10.1038/nm.4428. View